MY134211A - Novel use - Google Patents

Novel use

Info

Publication number
MY134211A
MY134211A MYPI20021787A MYPI20021787A MY134211A MY 134211 A MY134211 A MY 134211A MY PI20021787 A MYPI20021787 A MY PI20021787A MY PI20021787 A MYPI20021787 A MY PI20021787A MY 134211 A MY134211 A MY 134211A
Authority
MY
Malaysia
Prior art keywords
conditions
bowel
functional
visceral pain
pain
Prior art date
Application number
MYPI20021787A
Inventor
Dr Douglas William Pierre Hay
Dr Gareth John Sanger
Dr Tadataka Yamada
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0112208A external-priority patent/GB0112208D0/en
Priority claimed from GB0129268A external-priority patent/GB0129268D0/en
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of MY134211A publication Critical patent/MY134211A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Abstract

A METHOD FOR THE TREATMENT AND/OR PROPHYLAXIS OF CONDITIONS CHARACTERISED BY ALTERED BOWEL FUNCTION AND/OR VISCERAL PAIN IN HUMANS OR NON-HUMAN MAMMALS, WHICH METHOD COMPRISES THE ADMINISTRATION OF AN EFFECTIVE, NON-TOXIC AND PHARMACEUTICALLY ACCEPTABLE AMOUNT OF AN HK3 RECEPTOR ANTAGONIST, WHEREIN THE CONDITION CHARACTERISED BY ALTERED BOWEL FUNCTION AND/OR VISCERAL PAIN IS SELECTED FROM CERTAIN IRRITABLE BOWEL SYNDROME CONDITIONS, FUNCTIONAL ABDOMINAL BLOATING, FUNCTIONAL DIARRHEA, OTHER BOWEL CONDITIONS AND FUNCTIONAL ABDOMINAL PAIN.
MYPI20021787A 2001-05-18 2002-05-16 Novel use MY134211A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0112208A GB0112208D0 (en) 2001-05-18 2001-05-18 New use
GB0129268A GB0129268D0 (en) 2001-12-06 2001-12-06 Novel use

Publications (1)

Publication Number Publication Date
MY134211A true MY134211A (en) 2007-11-30

Family

ID=26246093

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20021787A MY134211A (en) 2001-05-18 2002-05-16 Novel use

Country Status (19)

Country Link
EP (1) EP1387687A4 (en)
JP (1) JP2004534761A (en)
KR (1) KR20040016865A (en)
CN (1) CN1269483C (en)
AR (1) AR045879A1 (en)
AU (1) AU2002303811B2 (en)
BR (1) BR0209662A (en)
CA (1) CA2447063A1 (en)
CZ (1) CZ20033115A3 (en)
HU (1) HUP0400966A2 (en)
IL (1) IL158701A0 (en)
MX (1) MXPA03010509A (en)
MY (1) MY134211A (en)
NO (1) NO20035121L (en)
NZ (1) NZ529462A (en)
PE (1) PE20021067A1 (en)
PL (1) PL367308A1 (en)
TW (1) TWI243678B (en)
WO (1) WO2002094187A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
KR101227627B1 (en) 2003-01-28 2013-01-31 아이언우드 파마슈티컬스, 인코포레이티드 Methods and compositions for the treatment of gastrointestinal disorders
TW200602055A (en) * 2004-03-30 2006-01-16 Smithkline Beecham Corp Spray dried pharmaceutical compositions
WO2005100997A2 (en) * 2004-04-16 2005-10-27 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with tachykinin receptor 3 (tacr3)
WO2007041479A2 (en) * 2005-09-30 2007-04-12 Smithkline Beecham Corporation Pharmaceutical compositions
TW201018662A (en) 2005-12-12 2010-05-16 Astrazeneca Ab Alkylsulphonamide quinolines
MX2009013293A (en) 2007-06-04 2010-02-15 Synergy Pharmaceuticals Inc Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2627848T3 (en) 2008-06-04 2017-07-31 Synergy Pharmaceuticals Inc. Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP2011528375A (en) 2008-07-16 2011-11-17 シナジー ファーマシューティカルズ インコーポレイテッド Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer, and other disorders
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2010078449A2 (en) 2008-12-31 2010-07-08 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
KR200452372Y1 (en) * 2010-05-14 2011-02-22 서일수 Communication line support device of construction lift
KR101034774B1 (en) * 2010-07-30 2011-05-17 (주)챔피온코리아 Lift device using the wire rope
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
JP6392754B2 (en) 2012-08-21 2018-09-19 アーデリクス，インコーポレーテッド Compounds and methods for inhibiting NHE-mediated reverse transport in the treatment of fluid retention or salt overload related diseases and gastrointestinal diseases
JP2016514671A (en) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド Guanylate cyclase agonists and uses thereof
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
SI2983667T1 (en) 2013-04-12 2019-09-30 Ardelyx, Inc. Nhe3-binding compounds and methods for inhibiting phosphate transport
CA2909752A1 (en) 2013-04-19 2014-10-23 Astrazeneca Ab A nk3 receptor antagonist compound (nk3ra) for use in a method for the treatment of polycystic ovary syndrome (pcos)
KR102272746B1 (en) 2013-06-05 2021-07-08 보슈 헬스 아일랜드 리미티드 Ultra-pure agonists of guanylate cyclase c, method of making and using same
JP2020505333A (en) 2017-01-09 2020-02-20 アルデリックス， インコーポレイテッド Inhibitors of NHE-mediated antiport
EP3565808A1 (en) 2017-01-09 2019-11-13 Ardelyx, Inc. Compounds useful for treating gastrointestinal tract disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2719311B1 (en) * 1994-03-18 1998-06-26 Sanofi Sa Compounds that are selective antagonists of the human NK3 receptor and their use as drugs and diagnostic tools.
US5434158A (en) * 1994-04-26 1995-07-18 Merck & Co., Inc. Spiro-substituted azacycles as neurokinin-3 antagonists
AR004735A1 (en) * 1995-11-24 1999-03-10 Smithkline Beecham Spa CHINOLEIN 4-AMIDO SUBSTITUTED, A PROCEDURE FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM AND THE USE OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT.
PL336942A1 (en) * 1997-05-23 2000-07-17 Smithkline Beecham Spa Derivatives of quinoline-4-carboxamide as antagonists of nk-2 and nk-3 receptor
KR20010075726A (en) * 1998-11-20 2001-08-09 파올로 비지, 엔리꼬 카쭐라니 Quinoline-4-carboxamide Derivatives as NK-3 and NK-2 Receptor Antagonists

Also Published As

Publication number Publication date
IL158701A0 (en) 2004-05-12
PE20021067A1 (en) 2003-02-02
BR0209662A (en) 2004-04-20
EP1387687A4 (en) 2006-07-05
NO20035121D0 (en) 2003-11-17
WO2002094187A3 (en) 2003-05-30
JP2004534761A (en) 2004-11-18
AR045879A1 (en) 2005-11-16
AU2002303811B2 (en) 2005-07-07
WO2002094187A2 (en) 2002-11-28
CN1269483C (en) 2006-08-16
EP1387687A2 (en) 2004-02-11
HUP0400966A2 (en) 2004-08-30
TWI243678B (en) 2005-11-21
NZ529462A (en) 2005-07-29
CN1509175A (en) 2004-06-30
KR20040016865A (en) 2004-02-25
NO20035121L (en) 2003-11-17
CA2447063A1 (en) 2002-11-28
CZ20033115A3 (en) 2004-09-15
PL367308A1 (en) 2005-02-21
MXPA03010509A (en) 2004-03-02

Similar Documents

Publication Publication Date Title
MY134211A (en) Novel use
NO20020792L (en) Treatment of restless leg syndrome with a combination of clonidine and opioid
AP9801272A0 (en) Use of an antagonist of ppar-alpha and ppr-gamma for the treatment of syndrom X.
EP1203586A3 (en) Compositions comprising a mast cell degranulation-blocking agent for treatment of endogenous, painful gastrointestinal conditions of non-inflammatory, non-ulcerative origin.
MXPA02012712A (en) N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity.
HK1044282A1 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
WO2002059107A8 (en) Substituted piperidines/piperazines as melanocortin receptor agonists
HK1038926A1 (en) Crf receptor antagonists and methods relating thereto
WO2001001972A3 (en) SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE
HK1038925A1 (en) Crf receptor antagonists and methods relating thereto crf
EP1889614A3 (en) Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
NZ334029A (en) Use of serotonin 5-HT1F agonist for the treatment of common colds or allergic rhinitis
WO1999038532A3 (en) Methods for the prevention and treatment of fibrosis and sclerosis
SI1532131T1 (en) Motilide compounds
PL352551A1 (en) C16 unsaturated analoques of prostaglandines selective in respect to fp
IL158806A0 (en) Tri-and tetraaza-acenaphthylen derivatives as crf receptor antagonists
WO2000053148A3 (en) Methods and compositions for treating erectile dysfunction
WO2002041894A3 (en) Selective dopamine d4 receptor agonists for treating sexual dysfunction
IL161600A0 (en) Compounds and method for the treatment of over-active bladder
WO2002085302A3 (en) Methods of treating intestinal inflammation
CA2322967A1 (en) Prophylactic, therapeutic agent for osteoporosis
AU8906201A (en) Methods and compositions for the treatment and prevention of sexual dysfunction
GB2411356A (en) Compositions and method for treating affective, painful or allergic disorders
CA2195053A1 (en) Agents for inhibiting accumulation of visceral fat
MXPA03010407A (en) Prevention of addiction in pain management.